

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM763083

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT
RESUBMIT DOCUMENT ID:	900716162

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
MELINTA THERAPEUTICS, LLC		08/23/2022	Limited Liability Company: DELAWARE

RECEIVING PARTY DATA

Name:	Silicon Valley Bank
Street Address:	3003 Tasman Drive, HF 150
City:	Santa Clara
State/Country:	CALIFORNIA
Postal Code:	95054
Entity Type:	Corporation: CALIFORNIA

PROPERTY NUMBERS Total: 9

Property Type	Number	Word Mark
Registration Number:	6755015	KIMYRSA
Registration Number:	4664703	ORBACTIV
Registration Number:	6583832	ORBACTIV (ORITAVANCIN)
Registration Number:	5566623	VABOMERE
Registration Number:	5681621	VABOMERE MEROPENEM AND VABORBACTAM FOR I
Registration Number:	5587889	
Serial Number:	90796299	MELINTA
Serial Number:	90796313	MELINTA
Serial Number:	90796332	MELINTA

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 800-494-5225

Email: ipteam@cogencyglobal.com

Correspondent Name: Stewart Walsh

Address Line 1: 1025 Connecticut Ave NW, Suite 712

Address Line 2: COGENCY GLOBAL Inc.
Address Line 4: Washington, D.C. 20036

ATTORNEY DOCKET NUMBER:	1767838 TM A
NAME OF SUBMITTER:	Gwendolyn Meccas
SIGNATURE:	/Gwendolyn Meccas/
DATE SIGNED:	10/24/2022

Total Attachments: 43

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page1.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page2.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page3.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page4.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page5.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page6.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page7.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page8.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page9.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page10.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page11.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page12.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page13.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page14.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page15.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page16.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page17.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page18.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page19.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page20.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page21.tif
source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd

LMA)#page22.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page23.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page24.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page25.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page26.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page27.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page28.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page29.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page30.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page31.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page32.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page33.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page34.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page35.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page36.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page37.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page38.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page39.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page40.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page41.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page42.tif

source=A - Amended and Restated Intellectual Property Security Agreement (Melinta) - Melinta (3rd LMA)#page43.tif

AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Amended and Restated Intellectual Property Security Agreement (this “**Agreement**”) is entered into as of August 23, 2022, by and between SILICON VALLEY BANK, a California corporation (“**Bank**”) and MELINTA THERAPEUTICS, LLC a Delaware limited liability company (“**Grantor**”). This Agreement amends and restates in its entirety, and replaces, that certain Intellectual Property Security Agreement dated as of December 22, 2020, by and between Grantor and Bank (the “**Prior Agreement**”).

RECITALS

A. Bank has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement by and among Bank, Grantor, MELINTA SUBSIDIARY CORP., a Delaware corporation (“**Subsidiary Corp.**”), TARGANTA THERAPEUTICS CORPORATION, a Delaware corporation (“**Targanta**”), and REMPEX PHARMACEUTICALS, INC., a Delaware corporation (“**Rempex**”, and together with Grantor, Subsidiary Corp. and Targanta, individually and collectively, jointly and severally, “**Borrower**”) dated as of December 22, 2020, as amended by that certain First Amendment to Loan and Security Agreement by and between Bank and Borrower dated as of May 3, 2022, as further amended by that certain Second Amendment to Loan and Security Agreement by and between Bank and Borrower dated as of July 25, 2022, and as further amended by that certain Third Amendment to Loan and Security Agreement by and between Bank and Borrower dated as of the date hereof (as the same has been, and as may be further amended, modified or supplemented from time to time, the “**Loan Agreement**”; capitalized terms used herein are used as defined in the Loan Agreement). Bank is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in its Copyrights, Trademarks, and Patents (as each term is described below) to secure the obligations of Grantor to Bank.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Bank a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of Borrower’s obligations to Bank, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. Subject to the terms and conditions of the Loan Agreement, to secure Borrower’s obligations to Bank, Grantor grants and pledges to Bank a security interest in all of Grantor's right, title and interest in, to and under its intellectual property

(all of which shall collectively be called the “**Intellectual Property Collateral**”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “**Copyrights**”);

(b) Any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know-how and operating manuals now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”);

(f) [Reserved];

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, or Trademarks and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, or Patents; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding anything to the contrary herein, the Intellectual Property Collateral shall not include any United States intent-to-use trademark or service mark applications filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. § 1051, at all times prior to the filing of a “Statement

of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto with the United States Patent and Trademark Office or otherwise.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials of the United States to record and register this Agreement upon request by Bank.

3. Authorization. Grantor hereby authorizes Bank to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement, and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

4. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Bank with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Execution in Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.

6. Successors and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Prior Agreement. Grantor and Bank hereby agree that, effective upon the execution and delivery of this Agreement by each such party, the terms and provisions of the Prior Agreement shall be and hereby are amended, restated and superseded in their entirety by the terms and provisions of this Agreement. Nothing herein contained shall be construed as a substitution or novation of the obligations of Grantor outstanding under the Prior Agreement or instruments securing the same, which obligations shall remain in full force and effect, except to the extent that the terms thereof are modified hereby or by instruments executed concurrently herewith. Nothing expressed or implied in this Agreement shall be construed as a release or other discharge of Grantor from any of the obligations or liabilities under the Prior Agreement. Grantor hereby confirms and agrees that to the extent that the Prior Agreement purports to assign or pledge to the Bank, or to grant to Bank a security interest in or lien on, any collateral as security for the Obligations, such pledge, assignment or grant of the security interest or lien is hereby ratified and confirmed in all respects and shall remain effective as of the first date it became effective.

8. Governing Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and


construed in accordance with, the laws of the United States and the State of New York, without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction).

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

MELINTA THERAPEUTICS, LLC


By:  _____
05150EFB2D3345C...

Name: Christine Ann Miller

Title: President and Chief Executive Officer

BANK:

SILICON VALLEY BANK

By:  _____
C79370D0BDAA4B7...

Name: John Sansone

Title: Vice President

[Signature Page to Amended and Restated Intellectual Property Security Agreement (Melinta)]

EXHIBIT A

Copyrights

Description

Registration/
Application
Number

Registration/
Application
Date

None.

EXHIBIT B**Patents**

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
ANTIMICROBIAL COMPOSITIONS WITH EFFERVESCENT AGENTS	United States of America	16/774709	28-Jan-2020		
EFFERVESCENT DELAFLOXACIN COMPOSITIONS AND PROCESSES OF MAKING THE SAME	Colombia	NC2016/0006106	19-Jun-2015	35883	9/2/2019
ANTIMICROBIAL EFFERVESCENT FORMULATION	Bolivia	SP-0129-2015	22-Jun-2015		
COMPOSITIONS OF DELAFLOXACIN, CAPTISOL AND MEGLUMINE	Colombia	11-071.900	12-Nov-2009	4851	8/26/2013
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Albania	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Austria	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Austria	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Australia	2011289615	08-Aug-2011	2011289615	8/20/2015
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Belgium	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Belgium	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Bulgaria	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Switzerland	11816882.2	08-Aug-2011	2603514	7/18/2018

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Switzerland	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Czech Republic	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Czech Republic	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Germany	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Germany	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Denmark	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Denmark	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Estonia	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	European Patent Convention	20156442.4	08-Aug-2011	3666778	11/10/2021
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Finland	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Finland	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	France	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	France	18183968.9	08-Aug-2011	3412676	2/12/2020

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	United Kingdom	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	United Kingdom	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Greece	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Greece	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Hong Kong	19124876.4	08-Aug-2011	40001622	2/11/2021
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Croatia	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Hungary	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Hungary	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Ireland	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Ireland	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Iceland	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Iceland	18183968.9	08-Aug-2011	3412676	2/12/2020

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Italy	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Korea, Republic of	10-2013-7005086	08-Aug-2011	10-1987091	6/3/2019
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Korea, Republic of	10-2019-7015866	08-Aug-2011	10-2087313	3/4/2020
A CRYSTALLINE FORM OF CYCLIC BORONIC ACID ESTER DERIVATIVES	Korea, Republic of	10-2020-7006463	08-Aug-2011	10-2205755	1/15/2021
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Lithuania	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Luxembourg	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Latvia	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Monaco	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	North Macedonia	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Malta	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Malaysia	PI2021001118	08-Aug-2011		
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Netherlands	11816882.2	08-Aug-2011	2603514	7/18/2018

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Netherlands	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Norway	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Norway	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	New Zealand	607354	08-Aug-2011	607354	5/1/2015
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Poland	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Poland	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Portugal	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Portugal	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Romania	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Romania	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Serbia	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Sweden	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Sweden	18183968.9	08-Aug-2011	3412676	2/12/2020

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Slovenia	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Slovakia	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	San Marino	18183968.9	08-Aug-2011	3412676	2/12/2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Turkey	11816882.2	08-Aug-2011	2603514	7/18/2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Turkey	18183968.9	08-Aug-2011	3412676	2/12/2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Austria	SZ19/2019	29-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Austria	SZ18/2019	29-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Belgium	2019C/515	28-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Belgium	2019C/514	28-Mar-2019		
VABORBACTAM	Bulgaria	2020/0019	10-Jul-2020		
VABORBACTAM/MEROPENEM	Bulgaria	2020/0018	10-Jul-2020		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Switzerland	C02603514/01	01-Nov-2021	C02603514/01	2/9/2022

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Switzerland	C02603514/02	01-Nov-2021	C02603514/02	12/7/2021
VABORBACTAM	Cyprus, Republic of	SPCCY2020020	10-Jul-2020		
VABORBACTAM/MEROPENEM	Cyprus, Republic of	SPCCY2020019	10-Jul-2020		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Czech Republic	SPC/CZ2019/632	28-Mar-2019	632	10/8/2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Czech Republic	SPC/CZ2019/633	28-Mar-2019	633	10/8/2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Germany	122019000026.7	28-Mar-2019	122019000026	2/10/2022
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Germany	122019000027.5	28-Mar-2019	122019000027	2/10/2022
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Denmark	CA201900016	28-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Denmark	CA201900015	28-Mar-2019		
VABORBACTAM	Estonia	C20200018	09-Jul-2020	C20200018	5/27/2021
VABORBACTAM/MEROPENEM	Estonia	C20200017	09-Jul-2020	C20200017	5/27/2021
VABORBACTAM AND/OR A SALT AND/OR HYDRATE	Finland	C20190015	29-Mar-2019		

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
THEREOF					
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Finland	C20190016	29-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	France	19C1022	28-Mar-2019	19C1022	2/14/2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	France	19C1021	28-Mar-2019	19C1021	8/6/2021
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	United Kingdom	SPC/GB19/020	21-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	United Kingdom	SPC/GB19/021	21-Mar-2019		
VABORBACTAM	Croatia	S20200017A	10-Jul-2020		
VABORBACTAM/MEROPENEM	Croatia	S20200016A	10-Jul-2020		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Hungary	S1900017	02-Apr-2019	S000576	11/9/2021
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Hungary	S1900018	02-Apr-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Ireland	2019/017	28-Mar-2019	2019/017	10/9/2020

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Ireland	2019/018	28-Mar-2019	2019/018	10/9/2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Iceland	SPC261	28-Mar-2019	SPC261	3/15/2021
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Iceland	SPC262	28-Mar-2019	SPC262	3/15/2021
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Lithuania	PA2020521	10-Jul-2020	C3412676	2/2/2022
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Lithuania	PA2020519	10-Jul-2020		
VABORBACTAM	Luxembourg	LUC00169	06-Jul-2020		
VABORBACTAM/MEROPENEM	Luxembourg	LUC00168	06-Jul-2020		
VABORBACTAM	Latvia	CLV20200026	08-Jul-2020	CLV20200026	2/20/2021
VABORBACTAM/MEROPENEM	Latvia	CLV20200025	08-Jul-2020	CLV20200025	2/20/2021
VABORBACTAM	Malta	156/2020	10-Jul-2020	156/2020	9/22/2020
VABOMERE - MEROPENEUM/VABORBACTAM	Malta	155/2020	10-Jul-2020	155/2020	9/22/2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Netherlands	300978	28-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM	Netherlands	300977	28-Mar-2019		

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
TRIHYDRATE					
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Norway	2019013	28-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Norway	2019014	28-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Poland	DPO.0565	29-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Poland	DPO.0564	29-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Portugal	967	28-Mar-2019	967	6/24/2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Portugal	966	28-Mar-2019	966	6/17/2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Sweden	1990019-0	28-Mar-2019	1990019-0	6/11/2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Sweden	1990017-4	28-Mar-2019	1990017-4	6/11/2020

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
VABORBACTAM	Slovakia	PDO 8-2020	13-Jul-2020		
VABORBACTAM/MEROPENEM	Slovakia	PDO 9-2020	13-Jul-2020		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Albania	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Austria	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Belgium	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Bulgaria	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Switzerland	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Cyprus, Republic of	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Czech Republic	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Germany	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Denmark	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Estonia	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	European Patent Convention	19186092.3	30-Apr-2015		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Finland	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	France	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	United Kingdom	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Greece	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Croatia	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Hungary	15788682.1	30-Apr-2015	3140310	8/7/2019

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Ireland	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Iceland	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Liechtenstein	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Lithuania	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Luxembourg	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Latvia	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	North Macedonia	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Malta	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Netherlands	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Norway	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Poland	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Portugal	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Romania	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Serbia	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Sweden	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Slovenia	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Slovakia	15788682.1	30-Apr-2015	3140310	8/7/2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Turkey	15788682.1	30-Apr-2015	3140310	8/7/2019

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
SALTS AND POLYMORPHS OF CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	European Patent Convention	15788658.1	29-Apr-2015		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVES	Germany	15870720.8	09-Dec-2015	3233869	9/25/2019
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVES	France	15870720.8	09-Dec-2015	3233869	9/25/2019
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVES	United Kingdom	15870720.8	09-Dec-2015	3233869	9/25/2019
DOSAGE REGIMEN OF VABORBACTAM AND MEROPENEM FOR TREATING BACTERIAL INFECTIONS IN SUBJECTS WITH REDUCED RENAL FUNCTION	European Patent Convention	16783764	20-Apr-2016		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	United Arab Emirates	P6000635/2020	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Australia	2018360502	30-Oct-2018		
METHODS OF MAKING A COMPOUND OF FORMULA (E), FORMULA (B), FORMULA (D), FORMULA (C), AND COMPOUNDS OF FORMULA (II) AND FORMULA (I)	Brazil	BR112020008498-0	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Canada	3080763	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Chile	01143-2020	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Chile	0000000	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	China (People's Republic)	201880079247.3	30-Oct-2018		

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Colombia	NC2020/0006299	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Algeria	200270	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Egypt	649/2020	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	European Patent Convention	18874877.6	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Hong Kong	62021026513.3	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Indonesia	P00202003809	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	India	202037020993	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Jordan	PCT/JO/2020/101	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Japan	2020-543266	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Korea, Republic of	10-2020-7015638	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Mexico	MX/a/2020/004425	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Malaysia	PI2020001139	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	New Zealand	764335	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Philippines	1/2020/550544	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Saudi Arabia	520411905	30-Oct-2018		

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Singapore	11202003762V	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Thailand	2001002464	30-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	United States of America	16/760369	29-Apr-2020		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	Vietnam	1-2020-02894	30-Oct-2018		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	China (People's Republic)	201880012912.7	31-Jan-2018		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	European Patent Convention	18747999.3	31-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Australia	2018205327	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	China (People's Republic)	201880006135.5	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	European Patent Convention	18735813	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Malaysia	PI2019003938	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	New Zealand	755141	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	United Arab Emirates	P6000488/2020	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Australia	2018345317	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Canada	3078238	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Chile	00892-2020	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	China (People's Republic)	201880072552.X	01-Oct-2018		

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
	Republic)				
METHODS OF TREATING BACTERIAL INFECTIONS	Colombia	NC2020/0005419	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Algeria	200232	01-Oct-2018	11091	7/13/2021
METHODS OF TREATING BACTERIAL INFECTIONS	European Patent Convention	18863923.1	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Hong Kong	62021025781.7	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Indonesia	P00202003200	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Jordan	JO/PCT/2020/75	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Japan	2020-519066	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Korea, Republic of	10-2020-7012784	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Mexico	MX/a/2020/003670	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Malaysia	PI2020001141	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	New Zealand	763387	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Philippines	1/2020/550249	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Saudi Arabia	520411705	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Singapore	11202003009Q	01-Oct-2018	11202003009Q	3/10/2022
METHODS OF TREATING BACTERIAL INFECTIONS	Thailand	2001001955	01-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Taiwan	107134824	02-Oct-2018		
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	China (People's Republic)	201180046975.2	08-Aug-2011	ZL201180046975.2	10/26/2016

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Hong Kong	13113312.9	08-Aug-2011	HK1185883	7/12/2019
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	India	1146/DELNP/2013	08-Aug-2011	391496	3/9/2022
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	India	202118035169	08-Aug-2011		
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Malaysia	PI2013000386	08-Aug-2011	MY-188960-A	1/14/2022
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Russian Federation	2013104951	08-Aug-2011	2599791	9/21/2016
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Singapore	2013009378	08-Aug-2011	187757	10/5/2018
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVES	China (People's Republic)	201580072622.8	09-Dec-2015	ZL201580072622.8	5/31/2019
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVES	India	201717025004	09-Dec-2015	355484	1/7/2021
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVES	India	202018046526	09-Dec-2015		
METHODS OF TREATING BACTERIAL INFECTIONS	China (People's Republic)	201680023884.X	20-Apr-2016		
METHODS OF TREATING BACTERIAL INFECTIONS	China (People's Republic)	202110100198.0	20-Apr-2016		
METHODS OF TREATING BACTERIAL INFECTIONS	Hong Kong	18109076.8	20-Apr-2016		
METHODS OF TREATING BACTERIAL INFECTIONS	Hong Kong	42021041925.5	20-Apr-2016		
METHODS OF TREATING BACTERIAL INFECTIONS	Indonesia	PID201906867	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Korea, Republic of	10-2019-7023321	08-Jan-2018		

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
METHODS OF TREATING BACTERIAL INFECTIONS	Philippines	1/2019/501606	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Singapore	11201906226Y	08-Jan-2018	11201906226Y	11/8/2021
TETRACYCLINE COMPOSITIONS	China (People's Republic)	201180033194.X	12-May-2011	201180033194.X	7/6/2016
TETRACYCLINE COMPOSITIONS	Hong Kong	13107808.2	12-May-2011	HK1180586	5/5/2017
TETRACYCLINE COMPOSITIONS	India	9794/DELNP/2012	12-May-2011		
TETRACYCLINE COMPOSITIONS	Russian Federation	2012147527	12-May-2011	2647972	3/21/2018
TETRACYCLINE COMPOSITIONS	Singapore	2012082905	12-May-2011	185513	10/25/2017
TETRACYCLINE COMPOSITIONS	Australia	2011252919	12-May-2011	2011252919	5/4/2017
TETRACYCLINE COMPOSITIONS	Korea, Republic of	10-2012-7031982	12-May-2011	10-1799304	11/14/2017
TETRACYCLINE COMPOSITIONS	New Zealand	707329	12-May-2011	707329	1/5/2017
METHODS OF TREATING BACTERIAL INFECTIONS WITH MINOCYCLINE	Canada	3098302	26-Apr-2019		
METHODS OF TREATING BACTERIAL INFECTIONS WITH MINOCYCLINE	China (People's Republic)	201980037125.2	26-Apr-2019		
METHODS OF TREATING BACTERIAL INFECTIONS WITH MINOCYCLINE	European Patent Convention	19796660.9	26-Apr-2019		
METHODS OF TREATING BACTERIAL INFECTIONS WITH MINOCYCLINE	Hong Kong	62021040842.8	26-Apr-2019		
METHODS OF TREATING BACTERIAL INFECTIONS WITH MINOCYCLINE	Jordan	PCT/JO/2020/271	26-Apr-2019		
METHODS OF TREATING BACTERIAL INFECTIONS WITH MINOCYCLINE	Mexico	MX/a/2020/011599	26-Apr-2019		
ANTHRAX	Australia			2007346657	10/24/2013
ANTHRAX	Canada			2664444	10/27/2015
ANTHRAX	EP			2068890	1/8/2014
ANTHRAX	Switzerland			2068890	1/8/2014

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
ANTHRAX	Germany			2068890	1/8/2014
ANTHRAX	Spain			2068890	1/8/2014
ANTHRAX	France			2068890	1/8/2014
ANTHRAX	United Kingdom			2068890	1/8/2014
ANTHRAX	Italy			2068890	1/8/2014
ANTHRAX	Israel			1977667	7/22/2016
ANTHRAX	United States of America			9089507	7/28/2015
C. DIFFICILE	Australia			2008298987	3/27/2014
C. DIFFICILE	Brazil				
C. DIFFICILE	Canada			2699550	6/18/2020
C. DIFFICILE	EA – 10 countries			17564	1/30/2013
C. DIFFICILE	EP			2195004	4/1/2015
C. DIFFICILE	Switzerland			2195004	4/1/2015
C. DIFFICILE	Germany			2195004	4/1/2015
C. DIFFICILE	Spain			2195004	4/1/2015
C. DIFFICILE	France			2195004	4/1/2015
C. DIFFICILE	GB			2195004	4/1/2015
C. DIFFICILE	Italy			2195004	4/1/2015
C. DIFFICILE	Japan			5591112	8/8/2014
C. DIFFICILE	United States of America			8,518,873	8/27/2013
C. DIFFICILE	United States of America			8,629,100	1/14/2014
C. DIFFICILE	United States of America			9220749	12/29/2015
BIOFILMS	United States of America			10,201,587	2/12/2019
BIOFILMS	EPO			2278989	5/16/2021
BIOFILMS	Switzerland			2278989	5/26/2021
BIOFILMS	Germany			2278989	5/26/2021
BIOFILMS	Spain			2278989	5/26/2021
BIOFILMS	France			2278989	5/26/2021
BIOFILMS	United Kingdom			2278989	5/26/2021
BIOFILMS	Italy			2278989	5/26/2021


Description	Country	App. No.	Filing Date	Patent No.	Issue Date
SIMPLIFI	Australia			2009285564	9/4/2014
SIMPLIFI	Australia			2013202360	7/7/2016
SIMPLIFI	Canada			2736860	4/28/2020
SIMPLIFI	China				
SIMPLIFI	EA – 10 countries			20490	11/28/2014
SIMPLIFI	EP			2337575	7/31/2015
SIMPLIFI	Austria			2337575	7/31/2015
SIMPLIFI	Belgium			2337575	7/31/2015
SIMPLIFI	Switzerland			2337575	7/31/2015
SIMPLIFI	Czech Republic			2337575	7/31/2015
SIMPLIFI	Denmark			2337575	7/31/2015
SIMPLIFI	Finland			2337575	7/31/2015
SIMPLIFI	France			2337575	7/31/2015
SIMPLIFI	Germany			2337575	7/31/2015
SIMPLIFI	United Kingdom			2337575	7/31/2015
SIMPLIFI	Greece			2337575	7/31/2015
SIMPLIFI	Hungary			2337575	7/31/2015
SIMPLIFI	Ireland			2337575	7/31/2015
SIMPLIFI	Italy			2337575	7/31/2015
SIMPLIFI	Netherlands			2337575	7/31/2015
SIMPLIFI	Norway			2337575	7/31/2015
SIMPLIFI	Poland			2337575	7/31/2015
SIMPLIFI	Portugal			2337575	7/31/2015
SIMPLIFI	Romania			2337575	7/31/2015
SIMPLIFI	Spain			2337575	7/31/2015
SIMPLIFI	Sweden			2337575	7/31/2015
SIMPLIFI	Turkey			2337575	7/31/2015
SIMPLIFI	EP				
SIMPLIFI	Japan			5782615	7/31/2015
SIMPLIFI	Mexico			322716	8/11/2014
SIMPLIFI	New Zealand			591525	7/1/2014
SIMPLIFI	United States of America			8,420,592	4/16/2013
SIMPLIFI	United States of America				


Description	Country	App. No.	Filing Date	Patent No.	Issue Date
serum binding	United States of America			9,682,061	6/20/2017
serum binding	Australia			2010245097	12/3/2015
serum binding	Canada			2760159	1/12/2021
serum binding	EP				
Glycopep. w/improved solubility	United States of America			8,901,072	12/24/2014
Disk Diffusion Assay	EP			2737077	11/11/2016
Disk Diffusion Assay	Switzerland			2737077	11/11/2016
Disk Diffusion Assay	Germany			2737077	11/11/2016
Disk Diffusion Assay	Spain			2737077	11/11/2016
Disk Diffusion Assay	France			2737077	11/11/2016
Disk Diffusion Assay	United Kingdom			2737077	11/11/2016
Disk Diffusion Assay	Italy			2737077	11/11/2016
Disk Diffusion Assay	United States of America			8,815,535	8/26/2014
Bacteremia	United States of America				
Bacteremia	EP				
Synergy with Polymyxin	United States of America			9,775,878	10/3/2017
High Purity ORI	United States of America			9,649,352	5/16/2017
High Purity ORI	United States of America			10,328,118	6/25/2019
Method of Making ORI	United States of America			10,864,249	12/15/2020
High Purity ORI	Australia			2015289602	10/8/2020
High Purity ORI	Brazil				
High Purity ORI	Canada				
High Purity ORI	China				
High Purity ORI	EP				
High Purity ORI	Hong Kong				
High Purity ORI	India			359618	2/26/2021
High Purity ORI	Japan			6712991	6/4/2020
High Purity ORI	Mexico				




Description	Country	App. No.	Filing Date	Patent No.	Issue Date
High Purity ORI	New Zealand			728401	12/1/2020
Oritavancin Formulations	Brazil				
Oritavancin Formulations	EP				
Oritavancin Formulations	Mexico				
Crystalline Forms of D-Glucitol, 1-Deoxy-1-(Methylamino)-, 1-(6-Amino-3,5 Difluoropyridine-2-Yl)-8-Chloro-6-Fluoro-1,4-Dihydro-7	United States of America	14/773655	03/07/2017	Pending	Pending
Method for treating infections	United States of America	15/696603	09/06/2017	Pending	Pending
Tetracycline compositions	United States of America	16/287639	02/27/2019	Pending	Pending
Methods of treating bacterial infections with Minocycline	United States of America	17/052141	04/26/2019	Pending	Pending
HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME	United States of America	15/439,206	22-Feb-2017	10328118	25-Jun-2019
HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME	United States of America	16/437361	11-Jun-2019	20190290723	26-Sep-2019
METHODS OF INHIBITING AND TREATING BIOFILMS USING GLYCOPEPTIDE ANTIBIOTICS	United States of America	12/936,722	02-Apr-2009	10201587	12-Feb-2019
RIBOSOME STRUCTURE AND PROTEIN SYNTHESIS INHIBITORS	United States of America	13/924,155	21-Jun-2013	8912150	16-Dec-2014







EXHIBIT C

Trademarks



Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
ORBACTIV	Brazil	907643558	5/5/2014	907643558	4/17/2018
ORBACTIV	Canada	1673540	4/22/2014	TMA1007968	10/31/2018
ORBACTIV	South Africa	201410290	4/22/2014	201410290	4/22/2014
ORBACTIV	United Kingdom	801204701	4/21/2014	801204701	4/6/2015
	Canada	1932002	11/22/2018		

Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
	United Kingdom	801444014	11/21/2018	801444014	6/11/2019
VABOMERE	Brazil	913463426	2/27/2017	913463426	2/19/2019
VABOMERE	Canada	1859804	9/27/2017	TMA1055555	9/20/2019
VABOMERE	Laos	40025	9/28/2017	41436	7/4/2018
VABOMERE	South Africa	2017/28149	9/27/2017		
VABOMERE	Switzerland	620342017	9/27/2017	713719	3/6/2018

Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
VABOMERE	Thailand	170134532	9/28/2017	201120952	9/24/2020
VABOMERE	United Kingdom	801374089	9/25/2017	801374089	4/10/2018
VABOMERE (STYLIZED)	Malaysia	2017068939	9/29/2017		
	Australia	1923174	4/30/2018	1923174	8/8/2018
	Brazil	914603221	4/30/2018	914603221	4/16/2019
	Colombia	SD20180033168	4/30/2018	639022	1/25/2020

Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
	European Union (Community)	17893784	4/28/2018	17893784	9/6/2018
	India	3821026	5/1/2018	3821026	11/12/2018
	Mexico	M2042022	4/30/2018	1900902	7/12/2018
	New Zealand	1091846	4/30/2018	1091846	11/1/2018
	Switzerland	726632018	4/30/2018	722860	10/23/2018
	United Kingdom	917893784	4/28/2018	917893784	9/6/2018







Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
KIMYRSA	Brazil	1578326	1/7/2021	501578326	2/15/2022
KIMYRSA	Canada	2089102	1/7/2021		
KIMYRSA	China (People's Republic)	1578326	1/7/2021	90039970	7/8/2021
KIMYRSA	European Union (Community)	1578326	1/7/2021	1578326	7/21/2021
KIMYRSA	Int'l Registration - Madrid Agreement / Protocol	1578326	1/7/2021	1578326	1/7/2021
KIMYRSA	Japan	1578326	1/7/2021	1578326	1/13/2022







Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
KIMYRSA	Mexico	2510150	1/7/2021	2388865	5/13/2022
KIMYRSA	United States of America	90039970	7/7/2020	6755015	6/7/2022
	United States of America	90796299	6/25/2021		
MELINTA	United States of America	90796313	6/25/2021		
	United States of America	90796332	6/25/2021		
ORBACTIV	Australia	1204701	4/21/2014	1626706	9/18/2014





Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
ORBACTIV	China (People's Republic)	1204701	4/21/2014	1204701	4/21/2014
ORBACTIV	Egypt	1204701	4/21/2014	1204701	4/21/2014
ORBACTIV	European Union (Community)	1204701	4/21/2014	1204701	4/6/2015
ORBACTIV	India	2721870	4/21/2014	1631882	8/23/2017
ORBACTIV	Int'l Registration - Madrid Agreement / Protocol	1204701	4/21/2014	1204701	4/21/2014
ORBACTIV	Japan	1204701	4/21/2014		

Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
ORBACTIV	Kazakhstan	1204701	4/21/2014	1204701	4/21/2014
ORBACTIV	Korea, Republic of	1204701	4/21/2014		
ORBACTIV	Mexico	M1494890	4/21/2014	1517985	2/26/2015
ORBACTIV	New Zealand	1204701	4/21/2014	1204701	11/15/2013
ORBACTIV	Norway	201406384	6/5/2014	1204701	4/21/2014
ORBACTIV	Russian Federation	1204701	4/21/2014	1204701	4/21/2014

Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
ORBACTIV	Singapore	T1408816C	4/21/2014	1204701	2/13/2015
ORBACTIV	Switzerland	1204701	4/21/2014	1204701	4/21/2014
ORBACTIV	Turkey	1204701	4/21/2014	201455248	2/23/2015
ORBACTIV	Ukraine	1204701	4/21/2014	1204701	4/21/2014
ORBACTIV	United States of America	86120316	11/15/2013	4664703	12/30/2014
ORBACTIV	Vietnam	1204701	4/21/2014	1204701	4/21/2014

Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
	Australia	1444014	11/21/2018	1982519	7/29/2019
	China (People's Republic)	1444014	11/28/2018	1444014	3/25/2019
	Egypt	1444014	11/21/2018	1444014	11/21/2018
	European Union (Community)	1444014	11/21/2018	1444014	6/11/2019
	Int'l Registration - Madrid Agreement / Protocol	1444014	11/21/2018	1444014	11/21/2018
	Japan	2019350704	11/21/2018	1444014	2/6/2020

Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
	Korea, Republic of	1444014	11/21/2018	1444014	
	Mexico	M2157203	11/21/2018	2014909	6/26/2019
	New Zealand	1444014	11/21/2018	1444014	5/23/2019
	Norway	201900430	1/10/2019	1444014	11/21/2018
	Singapore	40201900864W	11/21/2018	1444014	11/21/2018
	Switzerland	1444014	11/21/2018	1444014	11/21/2018

Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
	Turkey	201960933	11/21/2018	1444014	11/21/2018
	Ukraine	1444014	11/21/2018	1444014	11/21/2018
	United States of America	87935592	5/24/2018	6583832	12/7/2021
	Vietnam	1444014	11/21/2018	1444014	11/21/2018
VABOMERE	Australia	1374089	9/25/2017	1885901	5/23/2018
VABOMERE	China (People's Republic)	1374089	9/25/2017	1374089	9/25/2017

Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
VABOMERE	Colombia	SD20170087531	9/25/2017	598537	5/31/2018
VABOMERE	European Union (Community)	1374089	9/25/2017	1374089	4/10/2018
VABOMERE	India	3676408	9/25/2017		
VABOMERE	Int'l Registration - Madrid Agreement / Protocol	1374089	9/25/2017	1374089	9/25/2017
VABOMERE	Israel	299919	9/25/2017	1374089	11/4/2018
VABOMERE	Japan	1374089	9/25/2017		

Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
VABOMERE	Korea, Republic of	1374089	9/25/2017		
VABOMERE	Mexico	M1971310	9/25/2017	1905851	7/26/2018
VABOMERE	New Zealand	1374089	9/25/2017	1374089	3/27/2018
VABOMERE	Singapore	40201722278U	9/25/2017	1374089	9/25/2017
VABOMERE	United States of America	87394992	3/31/2017	5566623	9/18/2018
VABOMERE	Vietnam	1374089	9/25/2017	1374089	9/25/2017

Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
	United States of America	87668224	11/1/2017	5681621	2/19/2019
	United States of America	87668177	11/1/2017	5587889	10/16/2018